Concepedia

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Anna Kalff, Jake Shortt, Julia Farr, Roger McLennan, Arthur Lui, Jeffrey W. Scott, Andrew Spencer

Haematologica · 2007 · 12 citations · 5 references

DOIFull text

Open access

Concepts

Abstract

LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.

References

5

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Purva Bali, Michael Pranpat, James E. Bradner et al. · Journal of Biological Chemistry · 2005 · 749 citations · Full text

, , +17

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

Wiernik Ph, PL Banks, DC Jr Case et al. · Blood · 1992 · 451 citations · Full text

, , +15

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3

Prince George, Purva Bali, Srinivas Annavarapu et al. · Blood · 2004 · 324 citations

, , +14

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

Giuseppe Visani, Patrizia Tosi, Pier Luigi Zinzani et al. · PubMed · 1994 · 129 citations

, , +16

Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia

Wiernik Ph, PL Banks, DC Jr Case et al. · Blood · 1992 · 33 citations

, , +15